Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Oct 26;12(22):2302-2304.
doi: 10.18632/oncotarget.28007.

Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer

Sasagu Kurozumi, Ayaka Katayama, Ken Shirabe, Jun Horiguchi, Emad A Rakha
Editorial

Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer

Sasagu Kurozumi et al. Oncotarget. .
No abstract available

Keywords: HER2 low; breast cancer; heterogeneity; triple negative.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST SK has received honoraria from Daiichi Sankyo Co. Ltd, Taiho Pharmaceutical Co. Ltd, Eli Lilly and Company, MSD K.K., AstraZeneca K.K., Chugai Pharmaceutical, and Novartis Japan.

Figures

Figure 1
Figure 1. Prospects on the changing of treatment-strategies based on HER2-expression for triple-negative cases.
In a present clinical practice, anti-HER2 treatments cannot be used for breast cancer with triple-negative type. Future translational research and clinical trial investigating the ability of new anti-HER2 antibody-drug conjugates (ADC) agents to HER2-heterogeneity type may lead to new treatment-strategies for triple-negative breast cancer.
See this image and copyright information in PMC

References

    1. Slamon D, et al.. N Engl J Med. 2011; 365:1273–83. 10.1056/nejmoa0910383. - DOI - PMC - PubMed
    1. Geyer CE, et al.. N Engl J Med. 2006; 355:2733–43. 10.1056/nejmoa064320. - DOI - PubMed
    1. Verma S, et al.. N Engl J Med. 2012; 367:1783–91. 10.1056/nejmoa1209124. - DOI - PMC - PubMed
    1. Wolff AC, et al.. J Clin Oncol. 2018; 36:2105–22. 10.1200/jco.2018.77.8738. - DOI - PubMed
    1. Eiger D, et al.. Cancers (Basel). 2021; 13:1015. 10.3390/cancers13051015. - DOI - PMC - PubMed

Publication types